Inactive Instrument

Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Biotechnology & Medical Research

Freeline Therapeutics Holdings plc Reports Earnings Results for the Nine Months Ended September 30, 2021

November 09, 2021 at 04:03 pm EST

Freeline Therapeutics Holdings plc reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported net loss was USD 105.69 million compared to USD 58.25 million a year ago. Basic loss per share from continuing operations was USD 2.96 compared to USD 8.39 a year ago.

Latest news about Freeline Therapeutics Holdings plc

Syncona’s Takeover of Freeline Therapeutics Becomes Effective	Feb. 20	MT
Freeline Therapeutics Holdings plc Announces Resignation of Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider from the Board	Feb. 20	CI
Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index	Feb. 19	CI
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc.	Feb. 19	CI
Freeline shareholders approve Syncona acquisition	Feb. 12	AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	Feb. 12	MT
Syncona says Freeline trial for Gaucher disease treatment positive	Jan. 19	AN
European Equities Traded in the US as American Depositary Receipts Gain Friday	Dec. 22	MT
Freeline Therapeutics Holdings plc Reports Earnings Results for the Nine Months Ended September 30, 2023	Dec. 01	CI
HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15	Nov. 28	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 22	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Nov. 22	MT
FTSE 100 Closes Down 0.17% After Autumn Statement	Nov. 22	DJ
Syncona agrees to buyout deal with Freeline Therapeutics	Nov. 22	AN
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	Nov. 22	MT
Sector Update: Health Care	Nov. 22	MT
Syncona to Take Over Freeline Therapeutics	Nov. 22	MT
Freeline Therapeutics to be Acquired by Syncona for $28.3 Million	Nov. 22	MT
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%	Nov. 10	DJ
ADRs Advance; Freeline Therapeutics Holdings Climbs 30%	Nov. 03	DJ
Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate	23-10-25	CI
Freeline Therapeutics Says FLT201 Showed 'Substantial' Drop in Gaucher Disease Biomarker in First Patient of Phase 1/2 Study	23-10-25	MT
FTSE 100 Closes Down 1.1% on Middle East Tensions	23-10-18	DJ
Wedbush Downgrades Freeline Therapeutics to Neutral From Outperform, Cuts Price Target to $5 From $8	23-10-18	MT
Syncona Submits Takeover Bid for Freeline Therapeutics	23-10-18	MT

Chart Freeline Therapeutics Holdings plc

Duration

Period

Chart Freeline Therapeutics Holdings plc

More charts

Company Profile

Freeline Therapeutics Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The Company is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. It is focused on improving patient lives through one-time treatments for chronic debilitating diseases. It uses its rationally designed AAV vector and capsid (AAVS3), along with promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient's bloodstream. Therapeutic AAV vectors consist of two main components, the capsid and the expression cassette (that contains the gene and the promoter). The Company is advancing clinical programs in Fabry disease and Gaucher disease Type 1. The Company's pipeline includes Fabry Disease FLT190 for the treatment of Fabry disease and Gaucher Disease FLT201 for the treatment of type 1 Gaucher disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - American Society of Gene and Cell Therapy Conference - Abstract Number: 2

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-11.11%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs